CAM
ACAD icon

Congress Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Congress Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-160,794
Closed -$3.58M – 377
2026
Q1 		$3.58M Buy
+160,794
New +$3.84M 0.03% 265

Other funds holding ACAD

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Congress Asset Management's ACAD Position: Q2 2026 in Review

Congress Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 160,794 shares — an estimated $3.58M sold.

Congress Asset Management first reported a position in ACAD in Q1 2026 and held it in 1 quarter. The position peaked at $3.58M in Q1 2026. 29 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Congress Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Congress Asset Management sold 160,794 Acadia Pharmaceuticals shares in Q2 2026, an estimated $3.58M.
  • Congress Asset Management first reported a position in Acadia Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Congress Asset Management's Acadia Pharmaceuticals position peaked at $3.58M in Q1 2026.
  • 29 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Congress Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.